31970-04-4

Usage

Uses

Used in Pharmaceutical Industry:
BENZYL 3-PYRROLINE-1-CARBOXYLATE 90 is used as a synthetic intermediate for the development of various pharmaceutical products, including inhibitors. Its unique structure allows for the creation of new compounds with potential therapeutic benefits.
Used in Synthesis of Pyrrolotriazine:
BENZYL 3-PYRROLINE-1-CARBOXYLATE 90 is used as a key component in the synthesis of a novel series of pyrrolotriazine compounds. These compounds have been found to act as pan-Aurora kinase inhibitors, which are important in the regulation of cell division and have potential applications in the treatment of various diseases, including cancer.

InChI:InChI=1/C12H13NO2/c14-12(13-8-4-5-9-13)15-10-11-6-2-1-3-7-11/h1-7H,8-10H2

Upstream product

• 109-96-6 3-Pyrroline 
• 501-53-1 benzyl chloroformate 
• 25070-76-2 benzyl diallylcarbamate 
• 95656-88-5 benzyl 3-hydroxypyrrolidine-1-carboxylate 
• 100858-33-1 (3R)-3-hydroxy-pyrrolidine-1-carboxylic acid benzyl ester 
• 75315-63-8 N-(benzyloxycarbonyl)succinimide 
• 98-88-4 benzoyl chloride 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 6913-92-4 1-benzyl-2,5-dihydro-1H-pyrrole 
• 63468-63-3 2,5-dihydro-1H-pyrrole hydrochloride 
• 1885-14-9 phenyl chloroformate 

Downstream Products

• 31865-25-5 benzyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 163439-83-6 (+)-(3R,4R)-1-benzyloxycarbonyl-3,4-dihydroxypyrrolidine 
• 134575-38-5 3-benzyl 6-ethyl (1α,5α,6β)-3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate 
• 146726-10-5 3-benzyl 6-ethyl (1α,5α,6α)-3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate 
• 945634-17-3 C₂₁H₂₅NO₆ 
• 869488-97-1 (3R,4S)-rel-3,4-difluoropyrrolidine-1-carboxylic acid benzyl ester 
• 504438-12-4 (1α,5α,6α)-6-hydroxy-3-azabicyclo[3.1.0]hexane-3-carboxylic acid benzyl ester 
• 134677-59-1 [1α,5α,6β]-3-Benzyloxycarbonyl-3-azabicyclo[3.1.0] hexane-6-carboxylic acid 
• 134575-39-6 (1α,5α,6β)-6-tert-butoxycarbonylamino-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid benzyl ester 
• 134575-15-8 (1α,5α,6α)-3-(benzyloxycarbonyl)-3-azabicyclo[3.1.0]hexane-6-carboxylic acid 
• 146726-08-1 (1α,5α,6α)-6-tert-butoxycarbonylamino-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid benzyl ester 
• 681424-87-3 (1α,5α,6α)-3-benzyloxycarbonyl-3-azabicyclo[3.1.0]hexane-6-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Completely Recyclable Monomers and Polycarbonate: Approach to Sustainable Polymers

It is of great significance to depolymerize used or waste polymers to recover the starting monomers suitable for repolymerization reactions that reform recycled materials no different from the virgin polymer. Herein, we report a novel recyclable plastic: degradable polycarbonate synthesized by dinuclear chromium-complex-mediated copolymerization of CO2 with 1-benzyloxycarbonyl-3,4-epoxy pyrrolidine, a meso-epoxide. Notably, the novel polycarbonate with more than 99 % carbonate linkages could be recycled back into the epoxide monomer in quantitative yield under mild reaction conditions. Remarkably, the copolymerization/depolymerization processes can be achieved by the ON/OFF reversible temperature switch, and recycled several times without any change in the epoxide monomer and copolymer. These characteristics accord well with the concept of perfectly sustainable polymers.

Synthesis and diacylglycerol acyltransferase-1 inhibition of azabicyclo[3.1.0]hexane derivatives

We identified azabicyclo[3.1.0]hexane derivatives that are active diacylglycerol acyltransferase-1 (DGAT)-1 inhibitor. Among the azabicyclo[3.1.0]hexane series, compound 6b showed good in vitro activity toward human DGAT-1, selectivity toward DGAT-2, and

DEUTERATED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IMAGING AGENTS

The present invention relates to deuterated and optionally detectably labeled compounds of formula (I): R1-A-R2 and formula (V) and salts thereof, wherein Rl, R2, A, and X10-X19 have any of

Tandem ring-closing metathesis/transfer hydrogenation: Practical chemoselective hydrogenation of alkenes

An operationally simple chemoselective transfer hydrogenation of alkenes using ruthenium metathesis catalysts is presented. Of great practicality, the transfer hydrogenation reagents can be added directly to a metathesis reaction and effect hydrogenation of the product alkene in a single pot at ambient temperature without the need to seal the vessel to prevent hydrogen gas escape. The reduction is applicable to a range of alkenes and can be performed in the presence of aryl halides and benzyl groups, a notable weakness of Pd-catalyzed hydrogenations. Scope and mechanistic considerations are presented.

CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF

Disclosed herein are immunoconjugates comprising an inhibitor of Eg5 linked to an antigen binding moiety such as an antibody, useful for treating cell proliferative disorders. Also disclosed are novel inhibitors of Eg5 that can be used either alone or as part of an immunoconjugate to treat cell proliferation disorders. The Eg5 inhibitors include compounds of this formula as described herein: [insert last structure from page 68 here] The invention further provides pharmaceutical compositions comprising these compounds and immunoconjugates, optionally including a therapeutic co-agent, and methods to use these compounds, conjugates and compositions for treating cell proliferation disorders.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

Enzymatic resolution of five membered heterocyclic bromohydrins

The lipase catalyzed resolution of trans-3,4-tetrahydrofuran and pyrrolidine bromohydrins by acylation or hydrolysis of their acylated derivatives has been studied. For both heterocycles, the best enantioselectivity was obtained using Candida antarctica l

N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES

The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.

3-HYDROXYPYRROLIDINE INHIBITORS OF 5?-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE

The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds